How to Read Ibogaine Research Yourself: A Verification Guide

If you have spent any time looking into ibogaine, you have encountered a strange asymmetry. The claims are enormous — addiction interrupted in a single session, decades of trauma resolved in a weekend — while the evidence base is small enough that you could read most of it in a week. Somewhere between those two facts, a lot of people make a decision that involves flying to another country and taking a cardiotoxic compound.

The good news is that you do not have to take anyone's word for what the research says. Clinical study records are public, free, and machine-readable. What most people lack is not access but vocabulary — a handful of technical distinctions that determine whether a study means what a website says it means.

This guide teaches those distinctions. For a summary of what the ibogaine research literature currently shows across addiction, trauma, and neurological applications, see our ibogaine research and clinical evidence overview. This article is about something different: how to check any such claim for yourself.

Start With the Registry, Not the Article

Most human studies conducted or intended for regulatory use are registered on ClinicalTrials.gov before they begin. Registration exists specifically to prevent selective reporting — you declare what you plan to measure before you know the answer.

You can search it directly. There is no login, and there is a public API. As of 9 August 2026, a search for ibogaine as an intervention returns nine registered studies. Nine. That number alone reframes a great deal of confident internet writing.

You can also browse a maintained view of these records through our ibogaine clinical trials tracker.

The Distinction That Matters Most: Observational vs Interventional

This is the single most important thing on this page.

An interventional study administers the drug. Researchers give participants ibogaine under a protocol and measure what happens. This is what most people picture when they hear "clinical trial."

An observational study does not administer anything. Researchers observe people who are already doing something — often people who have independently sought treatment elsewhere — and collect data before and after. No study drug is given. No dose is controlled by the investigators. There is usually no control group and no randomization.

Observational research is genuinely valuable. It is often the only ethical way to study something legally restricted, and it generates the signals that justify later trials. But it cannot establish that ibogaine caused an outcome, because the people who fly overseas for treatment are not a random sample of anyone. They are motivated, they are usually funded, and they typically arrive after other approaches failed.

The trap that catches almost everyone

An observational record can still list an intervention with the type DRUG.

The clearest example in the current registry is a Stanford University study (NCT04313712) examining ibogaine and magnesium in people with blast exposure and traumatic brain injury. Its intervention field describes ibogaine with magnesium treatment. Read quickly, it looks as though Stanford dosed veterans with ibogaine.

It did not. The study type is observational. In an observational record, that field describes an exposure being observed — in this case, treatment participants obtained on their own, outside the United States. The distinction is the difference between "we gave this to people" and "we measured people who did this."

This one misreading has propagated across a great deal of published ibogaine content. Always check studyType before interpreting an intervention field.

Learn the Status Vocabulary

Registry status terms are precise, and several of them are routinely misread as failure.

| Status | What it actually means | |---|---| | Recruiting | Currently enrolling participants | | Active, not recruiting | Enrollment closed; participants still being followed or data analyzed. Not a failure. | | Completed | Finished normally | | Terminated | Stopped early — this is a negative signal worth investigating | | Suspended | Paused, may resume | | Withdrawn | Closed before enrolling a single participant | | Unknown | The sponsor has not updated the record past its expected completion date |

"Active, not recruiting" is the most commonly misinterpreted of these. It simply means the doors closed. It is a normal, healthy phase of a study's life.

Withdrawn deserves particular attention, because a withdrawn study has an enrollment of zero. No one participated. Nothing was learned. A withdrawn record cited as evidence is not weak evidence — it is no evidence at all.

Read the Enrollment Number

Sample size is where enthusiasm meets arithmetic. In the current ibogaine registry, the completed interventional studies enrolled 9, 20, and 116 participants respectively — roughly 145 people in total across every completed trial that actually administered ibogaine under a protocol.

That is not nothing. An open-label study of nine people can absolutely justify a larger one. But it is a very different foundation than the phrase "clinically proven" implies, and any site using that phrase about ibogaine is describing something that does not yet exist.

What the Registry Shows Right Now

Verified against the ClinicalTrials.gov API on 9 August 2026:

Completed interventional studies (drug actually administered):

| Study | Sponsor | Location | Enrolled | |---|---|---|---| | Ibogaine in the treatment of alcoholism | University of São Paulo | Ribeirão Preto, Brazil | 9 | | Ibogaine in methadone detoxification | ICEERS | Reus, Spain | 20 | | Oral ibogaine in opioid withdrawal | atai Therapeutics | Manchester & London, UK | 116 |

Withdrawn interventional study: one, enrolling zero participants.

Observational studies: the remainder, including Stanford's TBI cohort (n=30, active/not recruiting), an Axial Therapeutic Research cohort in Northridge, California (n=52, active/not recruiting), and a University of California, Irvine neuroimaging study mapping ibogaine's neural dynamics in opioid use disorder (n=20, recruiting).

One pattern jumps out and is worth stating plainly: every completed interventional ibogaine trial has been conducted outside the United States. Brazil, Spain, the United Kingdom. The sole US interventional entry in the registry was withdrawn before enrolling anyone. Every currently active US study is observational.

That is not an accident of scientific interest. It is a direct consequence of scheduling and regulatory friction, which we cover in our guide to ibogaine's legal status across jurisdictions.

Five Questions to Ask of Any Ibogaine Claim

When you encounter a statistic — an 80% success rate, a dramatic symptom reduction, a headline percentage — run it through these.

1. Is there a study ID? A real claim traces to an NCT number or a citation. If a percentage appears with no source, treat it as advertising.

2. Observational or interventional? If observational, the study describes what happened to a self-selected group. It cannot establish causation.

3. How many people? Then ask how many completed follow-up, which is often a much smaller number.

4. How long was follow-up? Addiction outcomes at 30 days and at 12 months are very different measurements. Short windows flatter every intervention ever studied.

5. Who funded it, and does the site citing it sell the treatment? Not disqualifying — but relevant, and rarely disclosed.

What Research Cannot Tell You About Your Own Risk

There is a limit to what any of this resolves. The registry can tell you what has been studied; it cannot tell you whether you are a safe candidate. Ibogaine's most serious documented hazard is cardiac — it prolongs the QT interval, and deaths have occurred in unmonitored settings, frequently involving people with undiagnosed heart conditions or unrecognized drug interactions.

No amount of encouraging efficacy data changes that arithmetic for an individual with an untreated cardiac abnormality. Understanding ibogaine safety protocols and cardiac screening requirements matters more to your personal outcome than any efficacy statistic on this page.

If you are earlier in the process, our explainers on what ibogaine is and how it works and what the ibogaine treatment process involves provide the groundwork. Individual outcome reports — useful precisely because they are honest about being individual — are collected in our documented ibogaine case studies.

Frequently Asked Questions

How many ibogaine clinical trials are there? As of 9 August 2026, nine studies are registered on ClinicalTrials.gov with ibogaine as an intervention. Only four are interventional, and one of those was withdrawn without enrolling anyone.

Has ibogaine been proven to treat addiction? No. "Proven" implies replicated, adequately powered, controlled trials, which do not currently exist for ibogaine. The completed interventional studies are small and mostly open-label. Encouraging signals are not the same as proof.

Is the Stanford ibogaine study a clinical trial? It is a registered observational study, not an interventional trial. Participants obtained treatment independently outside the United States; Stanford researchers measured outcomes rather than administering the compound.

Does "active, not recruiting" mean a study failed? No. It means enrollment has closed while follow-up or analysis continues. The statuses that indicate problems are Terminated, Suspended, and Withdrawn.

Why are there so few US ibogaine trials? Ibogaine is a Schedule I substance in the United States, which imposes substantial regulatory burden on interventional research. Every completed interventional trial to date has been conducted abroad.

---

Medical disclaimer: This article is educational and is not medical advice. It does not endorse or recommend the use of ibogaine, which is a Schedule I controlled substance in the United States and carries documented risks including QT prolongation, cardiac arrhythmia, and death — particularly in unscreened or unmonitored settings, or in combination with other substances. Ibogaine Treatment Guide is an independent informational resource and is not a treatment provider. Always consult a qualified medical professional about your own circumstances. If you are in crisis or having thoughts of suicide, call or text 988 (Suicide & Crisis Lifeline) in the US, available 24/7.